Abstract:The Philadelphia chromosome is formed by a balanced, reciprocal translocation that pairs sequences from BCR on Chromosome 22 with sequences from ABL on Chromosome 9, resulting in the production of the constitutively active tyrosine kinase (TK) BCR-ABL. Depending on the location of the breakpoint within BCR, three different sizes of BCR-ABL may form, each associated with distinct clinical sequelae. Previous studies identified a functional domain within the BCR sequences preserved by the more-indolent forms of BCR-ABL (i.e., p210 and p230) that demonstrates a constitutive Rho guanine nucleotide exchange factor (RhoGEF) activity. Using the structurally derived S509A mutation, which does not affect TK activity but abrogates RhoGEF signaling, we, subsequently, showed that this feature regulates leukemia progression in mice. The RhoGEF domain was recently reported to contain two missense mutations (F547L and T654K) in a chronic myelogenous leukemia (CML) blast crisis (BC) patient, suggesting that it may play a role in human disease as well. To evaluate the clinical significance of this region, we, therefore, examined p210 BCR-ABL constructs containing these clinically derived RhoGEF mutations (CDRMs), both in isolation and in combination, using a murine bone marrow transplant (mBMT) model of CML. The mutations did not destabilize p210 BCR-ABL expression or TK activity but decreased RhoGEF signaling. Relative to mice transplanted with wild-type (WT) p210 BCR-ABL, those that received the CDRMs exhibited an earlier onset of disease, frequently developing previously unseen dermatologic involvement or myeloid sarcomas, but demonstrated significantly increased survival in an additive manner [Fig. 1]. While mice transplanted with WT p210 BCR-ABL exhibited neutrophilia that progresses to a less-differentiated phenotype at death, disease in the CDRM mice was characterized by eosinophilia and monocytosis with no maturation arrest. The most likely cause of death in mice transplanted with WT p210 BCR-ABL is widespread hematogenous involvement of the lungs resulting in acute respiratory distress. In contrast, mice receiving the CDRMs demonstrated pulmonary involvement which was limited to the bronchovascular bundles or subpleural space. This is consistent with a switch to lymphatogenous spread, likely secondary to skewed differentiation, and it implies an alternate cause(s) of death. To help determine the mechanism responsible for the observed differences in differentiation and maturation arrest, we next studied the CDRMs in vitro using the 32Dcl3 murine myeloid precursor cell line. A growing body of evidence suggests that the DNA damage response can affect lineage restriction in myeloid cells; it is also well-established that the accumulation of DNA damage is necessary for progression to BC. Accordingly, the CDRMs were associated with the restoration of p53 activation and the G1/S cell cycle checkpoint relative to WT p210 BCR-ABL. This suggests that the RhoGEF domain may be responsible for the suppression of the DNA damage response. Because the mBMT phenotype associated with the S509A mutation was distinct from that of the CDRMs, it may indicate that this capability is mediated by some functionality yet to be described. Importantly, the CDRMs were also associated with increased Src family kinase activity, which is thought to be a major mechanism of BCR-ABL-independent TK inhibitor resistance and minimal residual disease. Collectively, these results suggest that the BCR-ABL RhoGEF domain can influence disease progression and response to treatment in human leukemia. Disclosures No relevant conflicts of interest to declare.

Exogenous Cdk4 Overcomes Reducedcdk4 RNA and Inhibition of G1 Progression in Hematopoietic Cells Expressing a Dominant-Negative CBF – a Model for Overcoming Inhibition of Proliferation by CBF Oncoproteins

Promotive Effect of Decreased Cyclin E Threshold on Cell Proliferation

Target Inhibition of CBP Induced Cell Senescence in BCR-ABL- T315I Mutant Chronic Myeloid Leukemia

Abstract 576: Transforming Growth Factor-Beta (Tgf-Β) Inhibits Growth of Human Myeloid Leukemia Cells and Downregulates the Expression of CDK Inhibitor, P18ink4c.

Influence of CDK4/6 on proliferation and apoptosis of acute leukemia cells

Imatinib and Bortezomib Induce the Expression and Distribution of Anaphase-Promoting Complex Cdh1 in Blast Crisis of Chronic Myelogenous Leukemia

Data from BMP4 Administration Induces Differentiation of CD133+ Hepatic Cancer Stem Cells, Blocking Their Contributions to Hepatocellular Carcinoma

Chemoresistant Leukemia-Initiating Cell Expansion is Inhibited by Targeting Oncogenic Self-Renewal

P19ink4d Inhibits Proliferation and Enhances Imatinib Efficacy Through BCR-ABL Signaling Pathway in Chronic Myeloid Leukemia.

Imatinib blocks tyrosine phosphorylation of Smad4 and restores TGF-β growth-suppressive signaling in BCR-ABL1-positive leukemia

CBFβ-SMMHC, Expressed in M4Eo AML, Reduced CBF DNA-binding and Inhibited the G1 to S Cell Cycle Transition at the Restriction Point in Myeloid and Lymphoid Cells

[Effect of CPEB4 on Migration and Cycle of Chronic Myeloid Leukemia Cell]

A new regulatory motif in cell-cycle control causing specific inhibition of cyclin D/CDK4

Examination of Clinically-Derived p210 BCR/ABL Rhogef Mutations in a Murine Bone Marrow Transplantation Model of CML

BRD4 Degradation Blocks Expression of MYC and Multiple Forms of Stem Cell Resistance in Ph+ Chronic Myeloid Leukemia

Cell cycle and transcriptional control of human myeloid leukemic cells by transforming growth factor beta.

Functional Collaboration Between Different Cyclin-Dependent Kinase Inhibitors Suppresses Tumor Growth with Distinct Tissue Specificity

BCR-ABL and Interleukin 3 Promote Haematopoietic Cell Proliferation and Survival Through Modulation of Cyclin D2 and P27kip1 Expression

The Antiproliferative Activity of Kinase Inhibitors in Chronic Myeloid Leukemia Cells Is Mediated by FOXO Transcription Factors

Imatinib and Bortezomib Induce the Expression and Distribution of Anaphase-Promoting Complex Adaptor Protein Cdh1 in Blast Crisis of Chronic Myeloid Leukemia.

Inhibition of CK1ε Potentiates the Therapeutic Efficacy of CDK4/6 Inhibitor in Breast Cancer